NCT03927261 - PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

August 1, 2024

Study Completion Date

August 1, 2025

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndromes

Interventions

DRUG

PRGN-3006 T Cells

Participants will receive up to 2 intravenous (IV) administrations of PRGN-3006 T Cells with or without lymphodepletion and will be monitored for safety, efficacy, and correlative endpoints for up to 12 months following infusion.

Trial Locations (2)

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

55905

Mayo Clinic, Rochester